Solid Tumor
Conditions
Brief summary
The purpose of this study is to investigate safety, pharmacokinetics, effect of regulatory T cell depletion with Mogamulizumab for advanced or recurrent cancer patients.
Detailed description
This study consists of phase Ia and Ib portions for patients with solid tumors. Phase Ia portion is the standard 3+3 dose-escalation design with 0.1mg/kg, 0.5mg/kg and 1.0mg/kg of Mogamulizumab. Phase Ib portion is the randomized study comparing 0.1mg/kg and tolerated dose of Mogamulizumab based on the phase Ia portion to pursue safer and immunologically more efficient dose.
Interventions
BIOLOGICALMogamulizumab
Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.
Sponsors
Aichi Medical University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with histologically confirmed, CCR4 negative lung, stomach, esophageal, ovarian or skin cancer. 2. Patients with therapy-resistant cancer. Patients with recurrent cancer or advanced cancer who refused standard therapies. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status is 0, 1 or 2. 4. Patients should be 20 years or older at the time of informed consent. 5. No serious dysfunction of major organs (bone marrow, heart, lung, liver and kidney) and meet the following conditions ; 1) WBC count : \>=1,500/mm3 2) Hemoglobin : \>=8.0g/dL 3) Platelet count : \>=75,000/mm3 4) Serum total bilirubin : \<=2.0 x ULN 5) AST and ALT : \<=2.5 x ULN (Patients with hepatic infiltration which is attributed to primary disease\<=5.0 x ULN) 6) Serum creatinine : \<=1.5 mg/dL 7) SpO2 : \>=93 % 8) ECG : No abnormal findings. 9) EF : \>=50 % 6. Agree to use birth control including condom etc. from the time of obtaining the first consent to 24 weeks after the final administration of the study drug (except female after menopause (1 year or more after the last menstruation) and female/male after the operation for sterilization). 7. Given written informed consent. 8. Patients who can be hospitalized from the day of first administration to the next day. 9. Patients who have target lesions measurable by RECIST ver.1.1. 10. Life expectancy \>= 3 months.
Exclusion criteria
1. Patients with HIV antibody positive. 2. Patients with HCV antibody positive. 3. Patients with autoimmune disease. 4. Patients with HBs antigen or HBV-DNA positive. 5. History of serious anaphylaxis induced by antibody preparation. 6. Patients with double cancer. 7. Within 4 weeks after treatment with anticancer agent, immune suppressant, immune enhancer, cytokine therapy, radiotherapy or surgery for the primary disease. 8. Pregnant or breast-feeding females and females who have a possibility of pregnancy. 9. Patients with active infection. 10. Patients with psychosis or dementia. 11. Patients who need continuous systemic administration of adrenocorticosteroid. 12. Patients who have received hematopoietic stem cell transplantation. 13. Patients who have presence or suspicion of CNS involvement. 14. Patients who are administered the other investigational product within 4 weeks of the entry. 15. Patients treated with immunotherapy for cancer (e.g. cancer vaccine therapy) within 12 weeks of the entry. 16. Any other inadequacy for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of Treg decrease in PBMC compared to baseline | from baseline to every 4 weeks until data cut off |
| Cmax of Mogamulizumab | from day 0 to 28 days after the final administration, an expected average of 12 weeks. |
| Ctrough of Mogamulizumab | from day 0 to 28 days after the final administration, an expected average of 12 weeks. |
| AUC0-7day of Mogamulizumab | from day 0 to 28 days after the final administration, an expected average of 12 weeks. |
| Maximum tolerated dose(MTD) of Mogamulizumab | from first administration until day 28 |
| Dose limiting toxicity(DLT) of Mogamulizumab | from first administration until day 28 |
| Number of adverse events | from first administration to 24 weeks after the final administration, an expected average of 32 weeks. |
Secondary
| Measure | Time frame |
|---|---|
| Median progression free survival rate | from baseline to every 12 weeks, until data cut off (expected date is March 2016) |
| Median Overall survival rate | from baseline to every 12 weeks, until data cut off |
| Objective tumor response rate according to RECIST | from baseline to every 12 weeks, until data cut off |
Countries
Japan
Outcome results
None listed